DRI Healthcare Trust (TSE:DHT.UN) Price Target Cut to C$19.00

DRI Healthcare Trust (TSE:DHT.UN) had its price target decreased by stock analysts at Canaccord Genuity Group from C$19.50 to C$19.00 in a research report issued on Wednesday, BayStreet.CA reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 15.85% from the company’s previous close.

Several other research analysts also recently commented on the company. National Bankshares lifted their price target on DRI Healthcare Trust from C$22.00 to C$23.50 and gave the stock an “outperform” rating in a research report on Friday, March 1st. CIBC lifted their price target on DRI Healthcare Trust from C$19.50 to C$20.00 and gave the stock an “outperform” rating in a research report on Wednesday. Raymond James upgraded DRI Healthcare Trust from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from C$22.00 to C$24.00 in a research report on Friday, March 1st. Stifel Nicolaus boosted their price objective on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, Scotiabank boosted their price objective on DRI Healthcare Trust from C$22.00 to C$24.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of C$21.50.

DRI Healthcare Trust Stock Up 2.8 %

TSE DHT.UN traded up C$0.45 during trading on Wednesday, hitting C$16.40. The company’s stock had a trading volume of 35,640 shares, compared to its average volume of 34,314. The business’s 50 day moving average is C$16.22. DRI Healthcare Trust has a 52 week low of C$8.85 and a 52 week high of C$17.43.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.